Annual Cash & Cash Equivalents
$118.32 M
-$33.57 M-22.10%
December 31, 2023
Summary
- As of February 7, 2025, APGE annual cash & cash equivalents is $118.32 million, with the most recent change of -$33.57 million (-22.10%) on December 31, 2023.
- During the last 3 years, APGE annual cash & cash equivalents has fallen by -$33.57 million (-22.10%).
- APGE annual cash & cash equivalents is now -22.10% below its all-time high of $151.89 million, reached on December 31, 2022.
Performance
APGE Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$118.78 M
-$188.52 M-61.35%
September 30, 2024
Summary
- As of February 7, 2025, APGE quarterly cash and cash equivalents is $118.78 million, with the most recent change of -$188.52 million (-61.35%) on September 30, 2024.
- Over the past year, APGE quarterly cash and cash equivalents has increased by +$464.00 thousand (+0.39%).
- APGE quarterly cash and cash equivalents is now -75.53% below its all-time high of $485.46 million, reached on March 31, 2024.
Performance
APGE Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
APGE Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -22.1% | +0.4% |
| 3 y3 years | -22.1% | -5.0% |
| 5 y5 years | -22.1% | -5.0% |
APGE Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -22.1% | at low | -75.5% | +0.4% |
| 5 y | 5-year | -22.1% | at low | -75.5% | +0.4% |
| alltime | all time | -22.1% | at low | -75.5% | +0.4% |
Apogee Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $118.78 M(-61.3%) |
| Jun 2024 | - | $307.30 M(-36.7%) |
| Mar 2024 | - | $485.46 M(+310.3%) |
| Dec 2023 | $118.32 M | $118.32 M(-37.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2023 | - | $188.27 M(+50.5%) |
| Jun 2023 | - | $125.07 M(-11.5%) |
| Mar 2023 | - | $141.33 M(-7.0%) |
| Dec 2022 | $151.89 M | $151.89 M |
FAQ
- What is Apogee Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Apogee Therapeutics?
- What is Apogee Therapeutics annual cash & cash equivalents year-on-year change?
- What is Apogee Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Apogee Therapeutics?
- What is Apogee Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Apogee Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of APGE is $118.32 M
What is the all time high annual cash & cash equivalents for Apogee Therapeutics?
Apogee Therapeutics all-time high annual cash & cash equivalents is $151.89 M
What is Apogee Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, APGE annual cash & cash equivalents has changed by -$33.57 M (-22.10%)
What is Apogee Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of APGE is $118.78 M
What is the all time high quarterly cash and cash equivalents for Apogee Therapeutics?
Apogee Therapeutics all-time high quarterly cash and cash equivalents is $485.46 M
What is Apogee Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, APGE quarterly cash and cash equivalents has changed by +$464.00 K (+0.39%)